Dr. Lindsay Rosenwald has made a name for himself on Wall Street where he is a well-respected venture capitalist and hedge fund manager. He also has a long-lasting reputation in various fields of medicine and life-sciences research. In the arenas of healthcare and biotechnology, he is a leader, always at the forefront of R&D innovations. His singular experience combining the reaches of science with the power of finance has given Dr. Rosenwald the keen ability to create new avenues of research as well as find promising companies to invest in. His contributions are as countless as they are impacting. Millions of people across the world have benefited from healthcare that is, today, more far-reaching, a reality that Dr. Rosenwald has helped to create. There is hardly another person who can compare with the level of achievements Dr. Rosenwald has collectively made in these various fields.

In the progress of his brilliant career, spanning almost two decades, Dr. Lindsay A. Rosenwald, has established and re-capitalized many public and private life-science and biotech companies.

After finishing up high school at Abington in 1973, Rosenwald began his college career at Pennsylvania State University. He graduated with a degree in Finance. He continued his education at the Temple University School of Medicine and completed his internship at Abington Medical Hospital. Thereafter, Rosenwald sustained his own private practice in medicine before moving on to other horizons. On Wall Street, he combined his two expert subjects, finance and medicine, and carving his way, he continued to walk the path to success.

Between 1994 and 2007, Rosenwald played the role of executive director for the Aries Funds. The Funds invested over $1 billion into healthcare. From 2002 to 2006, Rosenwald took another executive position, at the head of the Orion Fund which specifically invested in biotechnology initiatives, especially private investments in public equity.

Dr. Rosenwald established a non-profit organization called the Rosenwald Foundation. The organization is devoted to supporting many scientific, healthcare and educational companies.

Rosenwald’s approach to medicine in conjunction with finance has encouraged him on his unique path. His approach allows him to pursue new angles in medicine, biotechnology and life sciences.

Dr. Rosenwald is currently a director at the Republican Jewish Coalition and also serves as president of Paramount Group. The Paramount Group’s specialty is in investment banking, R&D, and equity management in life-sciences and biotechnology. One of Dr. Rosenwald’s most recent undertakings is the OpusPoint Partners, LLC which was created in 2009. The new company’s aim is to offer support to promising endeavors and new accomplishments in life-sciences and biotechnology. OpusPoint Partners is committed to ground-breaking innovations and technologies in these industries.

Notable achievements by Dr. Lindsay Rosenwald and his team include providing funding for numerous companies and drug candidates that show promise. Cougar Biotechnology Inc., in L.A., is one of these companies. Its primary mandate is fighting cancer and has recently produced a new drug for aggressive forms of prostate cancer called Abiraterone. In 2009, Johnson & Johnson gained possession of this auspicious company for $1 billion after negotiating with Dr. Rosenwald.

Dr. Rosenwald and OpusPoint Partners will continue to seek opportunities for projects like this one. With these kinds of initiatives, they hope to change the face of medicine and life sciences, at the same time changing the rest of the world.

By establishing solid relationships and building upon their successes, OpusPoint Partners, along with Dr. Rosenwald’s leadership, will meet their goals. They already have an entire host of avant-garde credits to their name. Dr. Rosenwald is a truly innovative leader. He was the first investor in the first obesity drug in the US market. He was also the first founder of a stem cell company that trades publicly. The development of the first public gene therapy company owes its development to Dr. Rosenwald. Other accomplishments that Rosenwald has been involved in include the first cancer vaccine made available to the public.

Currently, Dr. Lindsay Rosenwald and OpusPoint Partners seek to create strong relationships with other leaders that share the same values and attitude to business and who are also passionate about finding and supporting breakthrough technologies.

With this level of determination, skill and methodology, OpusPoint Partners and its two founders, Dr. Rosenwald and Michael S. Weiss, have a broad and stable future ahead of them. The investments that they collectively make are bound to leave a very lasting impression on the way we look at disease.

Today, OpusPoint Partners has retained its position at the forefront of the life science and healthcare industries, revolutionizing the way that money is allocated towards investments for the advancement of healthcare and life sciences with a view to improving the quality of life for people from all over the world. The company is confident that under the dual leadership of these two gentlemen, the healthcare industry will improve how diseases are diagnosed and how healthcare treatment is delivered to patients to continue to meet the needs of the patients more effectively.

OpusPoint Partners under the guidance of Dr. Lindsay Rosenwald has stood steadfast in its commitment to practice integrity and still attain all of its short and long term goals. They seek to form a team which includes both the investors and the researchers working together in a quest to advance the future of medical care. Working relationships such as these which bring together the investment with the biotechnology build on a foundation of trust that brings out a high measure of honesty in the investing and full disclosure in all the related company’s dealings. This is where the team put together by OpusPoint Partners is then able to discover emerging companies and invest funds and resources into these enterprises where promising results are already being seen in the fields of healthcare and life sciences.

There is fierce competition in this industry and as a result OpusPoint Partners has established a solid conglomeration of organizations that know that it is easy to get lost by employing tactics that are not very ethical, in order to beat the system and to improve their earnings when performing clinical trials. This conglomeration maintains its guiding principles which sticks to its integrity and forfeits the dangerous short cuts. This is the essence that makes OpusPoint partners unique, being fair and loyal to its employees and its investors and not compromising when it comes to the research and the development of drugs through all of the trial stages and the final manufacturing stages.

These policies ensure that OpusPoint Partners will continue to be trailblazers, providing invaluable assistance for public companies and for businesses that are now starting up. This assistance comes in the form of advisory services and investments, believing that the mission to improve innovative companies bring a corresponding increase in the volume of medical breakthroughs which occur and having a ripple effect of improving the lives of many people.

The commitment and dedication to improving the way in which biotech investing is done is maintained by imposing strong moral values and by using strong business practices. Investors are then afforded excellent returns with minimal risk, a straight forward formula that proves the worthiness of this methodology. The success of this commitment has not gone without its rewards. Dr. Rosenwald highlighted that in the past few years, the company far exceeded its performance projections and was instrumental in significantly improving the financial health of more than twenty companies, earning them excellent accolades in the areas of drug research and finance and also earning excellent risk adjusted returns for its investors.

The mission of transforming present day healthcare and medical techniques and procedures as expected is not an easy undertaking. Time and commitment backed with hard work will support the provision of funding and bring promising results without compromising the ethical standards of the industry or losing earnings.

Dr. Lindsay Rosenwald is a member of the Board of Directors of the Republican Jewish Coalition and has formed many allegiances with many key individuals in the biotechnology financial sector. His illustrious career includes more than seventeen years as a Wall Street biotechnology investor. Dr. Rosenwald also founded the company Cougar Biotechnology Inc. in Los Angeles which is focused on the production of experimental drugs that treat cancer. One of these drugs has had remarkable success because of its effectiveness in the treatment of late stage prostate cancer. Johnson & Johnson acquired Cougar Biotech Labs on July 10th 2009 at a cost of over one billion dollars.

Dr. Lindsay Rosenwald managed the Aries Funds from 1994 to 2007 and this fund in the Year 2000, administered over $1B in healthcare investments. He also managed the Orion Fund from 2002 to 2006 which is a committed capital fund which is dedicated to private investments in biotechnology which also includes the PIPEs. With this wealth of experience come a medical degree from the Temple University School of Medicine and a finance degree from the Pennsylvania State University.

Dr. Rosenwald has established and re-capitalized quite a number of private and public sector biotechnology and life sciences companies. OpusPoint Partners anticipates that under his joint leadership, its successes will continue to set the trails ablaze well into the future.

Rosenwald and Weiss recognized the need to support the efforts of these developing companies and through OpusPoint Partners they are able to make the ideal notion of a world with less disease a possibility.

Both men have an overwhelming passion for creating and buttressing biotechnology and life science studies, and each has done so for over 20 years respectively. Lindsey Rosenwald and Michael Weiss have both independently and jointly invested in the development of biotech companies, helping them grow with their expertise and finely tuned ethic compass. It is their desires to not only see these life science and biotech firms succeed but to do so justly without deception.

Lindsay Rosenwald brings his extraordinary knowledge of both finance and biotechnology into play with OpusPoint Partners. Dr. Rosenwald has accomplished much in both his academic life and professional career. He holds two degrees, a Bachelor of Science in Finance from Pennsylvania State University and a Doctor of Medicine from Temple University School of Medicine.

Beyond Rosenwald’s academic achievements, he is a successful entrepreneur in the biotechnology field. He has been the driving force behind nearly 50 biotech companies over the span of 20+ years. One of these successful ventures was Cougar Biotechnology Inc., which among its many intriguing studies and drug trials a notable drug that helped thwart the growth prostate cancer in the late stages was discovered. In 2009 Lindsay Rosenwald sold Cougar Biotechnology to Johnson & Johnson for roughly one billion dollars. It is around this time that Rosenwald and Weiss teamed up for a new endeavor together.

With Dr. Rosenwald’s track record it is safe to say that that he has a knack for creating biotech success. Over the last few years with OpusPoint Partners he has aided approximately 20 biotech companies expand their businesses and studies to an extent that would have not been fathomable without the positive backing from the co-founders of this remarkable biotechnology investing firm.

OpusPoint Partners through the assistance of Lindsay Rosenwald as well as other biotech and life science investors are trying to bring a change to the field of drug development by giving biotech companies a fighting chance to make a positive impact in the world of medicine. This desire to influence innovation is based on strong ethical standards and a shared belief that integrity and advance technological thinking is what makes a good biotech business thrive.

This biotechnology investing company doesn’t solely work on their own, OpusPiont Partners also works alongside other investors, researchers, and corporations to find and contribute to the development of biotechnology firms that have great aspirations and ideas but lack the financials and bureaucratic know how to achieve their scientific goals. Lindsay Rosenwald is there to act as a guiding force pathing the way for emergent biotech companies to make a splash in the discovery of life saving drugs.

Dr. Rosenwald has proven time and time again that he is more than adept at making and administrating appropriate investments that are beneficial all around the board. Prior to his time at his current position he managed the Aries Fund (1994 or 2007) and the Orion Fund (2002 to 2006), both of which have made substantial contributions to furthering the efforts of biotechnology and life science companies and their initiatives.

Investors can be sure that with Lindsay Rosenwald managing their investments their risks will be minimal. Rosenwald and Weiss specifically hand pick biotech companies that show not only promise of positive investment growth but also of potentially successful drug research and trials. OpusPoint Partners are committed to staying true to their integrity on both the financial and science areas. A motto of prevailing honesty and discretion is what keeps investors with this company.

OpusPoint Partners sets itself apart from the competition by way of Rosenwald and Weiss’ dedication to remain transparent with their investors and being unyielding in their expectations for ethical research and trials of potentially lifesaving medicine. This steadfastness combined with the immense competency both men bring to the company ensures that OpusPoint Partners will experience continued progression and be a part of necessary discoveries in the biotech industry.

In less than two years at OpusPoint Partners, Lindsay Rosenwald has assisted in financing and mentoring more than 20 biotech companies through his robust financing connections in the biotechnology and life science sectors. OpusPoint Partners still has much more to accomplish and it is obvious that this company is in for a steady run of growth in the years to come.

Lindsay Rosenwald activities outside of his career include being a member of the Board of Directors of the Republican Jewish Coalition.

At OpusPoint Partners,we have a vision for an amazing future for the life science and healthcare industry. We believe in that vision so strongly that we are investingmoney and time to advance life sciences and biotechnology. We also believe in a strong, healthy future for human kind. With proper funding and research, we know that the quality of healthcare can be catapulted to a new and more effective level.

A Vision for the Future of Healthcare
With this vision in mind, Michael S. Weiss and Dr. LindsayRosenwald created OpusPoint Partners in 2009. These men have over 40 years of combined experience in the fields of healthcare, life sciences and biotechnology investing. Both are creative thinkers who have founded a number of biotech companies over the years.

Dr. Lindsay A. Rosenwaldhas most recently founded Cougar Biotechnology Inc.,which is a Los Angeles-based firm that focuses on the field of oncology. Cougar’s oncology portfolio includes some promising experimental drugs effective in treatingnumerousforms of cancer. One of those in particular has drawn the interests of researchers and investors. It has proven to work well at treating late-stage prostate cancer. Dr. Lindsay Rosenwald negotiated a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars in July of 2009.

Achieving the Objectives
The objective of Lindsay Rosenwald and OpusPoint Partners is twofold: to move forward withintegrity in achieving long-term goals and short-termgains, and to build solid relationships in both the world of investing and biotechnology.  By establishing strong relationships withother industry leaders who share similar values, they believe that these goals and objectives can be obtained without the sacrifice of their principles and standards.

For OpusPoint Partners, honest investing with full and open disclosure is more than just good business. This is a way of life.They currently work with a wide range of corporations to create a team approach to supporting emerging new businesses in an effort to reach critical goals.  Dr. Lindsay Rosenwald and OpusPoint Partners have made a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.These pioneers of research and investment believe in a better future for us all; a future where diseases are diagnosed and treated by more effective methods.
At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, believe in a world where people’s lives and health are greatly improved. They believe in creating a future where mankind achieves a much stronger quality of life. Through thisunique vision they are making a true difference in theirworld. In order to attain this dream of a better tomorrow for us all, their journey often involves providing advisory services to start-up businesses.  Sometimes it requires investing in publicly-traded companies.

Raising the Bar
Dr. Lindsay Rosenwald and OpusPoint Partners, is working to raise the bar for investors. Their efforts include advising emerging biotechnical research facilities. They believe that a strong moral compass along with sound business principles can significantly minimize risks and thereby maximize returns for investors and so far, this unique formula is proving to be successful.
For the past 17 years, Dr. Rosenwald has been a well-respected Wall Street biotechnology entrepreneur. His business ethics have not gone unnoticed. He has, in fact, been instrumental in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

An Innovative Business Philosophy
During his impressive twenty-year career, Dr. Lindsay Rosenwald has founded over fifty companies and managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. During the years of 2002 through 2006, he also managed the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

The philosophy behind OpusPoint Partners will be to build a successful life science and healthcare network that plays fair and does not take short cuts to reach its goals. Dr. Rosenwald and his associates know that the world we currently live in often provides too many opportunities for business leaders to use less than ethical tactics to try to manipulate outcomes of clinical trials and hence increase quarterly earnings.
OpusPoint Partners is a uniqueenterprise that continually reinforces its commitment to its employees and investors. Their promise is to deal fairly in all aspects of experimental drug trials. In the investigation and manufacture of experimental drugs, they are resolute about these vows.

The Benefits of Making the World a Better Place
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.
But revolutionizing these age-old medicaland healthcare techniques and procedures is no small task, nor is it for the faint of heart. In order to effect changes on such a grand scale requires commitment; it requires time and money.  It also involves a strong resolve to work hard within the ethical boundaries that other drug research companies may have discarded in favor of better profits.

Dr. Rosenwaldunderscoresthe fact that over the past few years, projected goals have already been surpassed. By applying best practices and processes, OpusPoint Partners moves ahead earning superior, risk-adjusted returns and helpingto finance and support more than 20 companies in the past two years alone.  This achievement is marked by a continuing commitment to the financial world and the world of drug research.

Credentials and Lifetime Achievements
Dr. LindsayRosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector.The future of OpusPoint Partners looks very promising with Dr. Rosenwald as its vanguard.

As with alllofty visionssuchas this, itwill take immense commitment from quality entrepreneurs to accomplish. Michael S. Weiss and Dr. Lindsay Rosenwald created OpusPoint Partners in 2009 with the idea of combining their 40 years of experience and business acumen working toward revolutionizing the fields of healthcare, life sciences and biotechnology investing. Both these men are well equipped to do this job and have already founded a number of biotech companies over the years.

With so much at stake, OpusPoint Partners along with Dr. Lindsay Rosenwald, is working toward making those leaps to advance and even transform the world of life sciences and biotechnology investing. Rosenwald, along with his team at OpusPoint, believe in a future where mankind significantly improves the quality of healthcare, as well as healthcare investing.

Advancements in the Future of Healthcare

Recently, Dr. Lindsay A. Rosenwaldfounded Cougar Biotechnology Inc. This Los Angeles-based company focuses on the field of oncology. Their oncology portfolio includes some very promising experimental drugs, which are proving to be effective in treatingnumerousforms of cancer.

One in particular has caused some excitement and drawn the interests of researchers and investors. It is a new drug that has been proven to work well at treating late-stage prostate cancer. In July of 2009, Dr. Lindsay Rosenwaldwas able to negotiate a deal with Johnson & Johnson for Cougar Biotech Labs at a price of approximately one billion dollars.

Realizing the Objectives
Lindsay Rosenwald and OpusPoint Partners believe they can continue to move forward with projects like these that alter healthcare significantly and produce results for the greater good of mankind. They achieve these goals with integrity, building solid relationships in both the world of investing and biotechnology.

Establishing robust relationships withother industry leaders who share similar values is a hallmark of the business strategy of both Dr. Lindsay Rosenwald and OpusPoint Partners. They believe in reaching goals and objectives through honesty, integrity and hard work. Their success has proven that you can obtain these objectives without the sacrifice ofprinciples and standards. Honest investing with full and open disclosure is more than just good business for OpusPoint Partners. This is the ideology they live by.

Creating New Partnerships for a Better Tomorrow
Dr. Lindsay Rosenwald and OpusPoint Partners currently work with a wide range of businesses and organizations to create a team approach for thesupport of emerging new businesses. They are making great strides toward building a powerful network of like-minded individuals who all possess a genuine commitment to discover and invest in innovative technologies in the fields of life sciences and healthcare.

With pioneers such as these in the areas of research and investment, you can be sure that thefuture of healthcare and life sciences will continue to flourish. These days, the medical field is well-aware of its need for diseases of all types to be diagnosed and treated by more effective methods. At OpusPoint Partners, Dr. Lindsay Rosenwald, his business partners and colleagues, know that the dream can become a reality with hard work and dedication.

The dream of a better tomorrow continues to be the fuel that fires this vision of a much stronger quality of life for us all. And thisunique vision of making a true difference in the world has become a driving force for Dr. Lindsay Rosenwald and OpusPoint Partners. History shows that dreams like this always take time, money and hard work, plus dedication from those involved.

Raising the Bar for Investors
Over the course of this journey, Dr. Lindsay Rosenwald and OpusPoint Partners must oftenprovide advisory services to start-up businesses. At times they also must invest in publicly-traded companies in order to move the vision forward.

One of their key objectives is to raise the bar for all investors. Whether working in the advisory capacity with emerging biotechnical research facilities or actually investing, OpusPoint followsa strong moral compass.With sound business principleslike these, the risks can be significantly minimizedand the returns for investors maximized. This uniqueformula has proven successful beyond anyone’s wildest dreams.

Utilizing Ethical Business Practices
The philosophy behind OpusPoint Partners is to build a positive and effective life science and healthcare network that plays fair and won’t take short cuts to reach its goals. Dr. Rosenwaldknows from experience, that today’s world often provides many opportunities for business leaders to use less than ethical tactics to try and manipulate outcomes of clinical trials with an eye toward greaterquarterly earnings. Does the end justify the means?

At OpusPoint Partners, the answer is a resounding no! This unique enterprise continually reinforces its commitment to its employees and investors to conduct business with higher standards than many of days gone by. In the investigation and manufacture of experimental drugs, they are resolute about this commitment to honest, above-board business dealings.

A Long and Fruitful Career
The future of OpusPoint Partners remains highly promising with Michael S. Weiss and Dr. Lindsay Rosenwald as its founders. They are utilizing their expertise in the fields of medicine and investments to effect some very real changes in the way diseases are diagnosed. They believe that the treatment of patients can be transformed.

Dr. Rosenwald, a well-respected Wall Street biotechnology entrepreneur, has worked for the past 17 years utilizing strong business ethics in the founding and re-capitalization of dozens of private and public biotechnology and life-sciences companies. He earned his M.D. from the Temple University School of Medicine and his B.S. in Finance from Pennsylvania State University.

Throughout an impressive twenty-year career, Dr. Lindsay Rosenwald has established over fifty companies. He also managed the Aries Funds from 1994 through 2007 with peak assets under his management in 2000 of over $1BB dedicated to healthcare investments. From 2002 to 2006, hemanaged the Orion Fund, which was a committed capital fund dedicated to private investments in biotechnology, in particular PIPEs.

Dr. Lindsay Rosenwald is currently a member of the Board of Directors at the Republican Jewish Coalition. He is one of the most broadly-informed and well-connected individuals in the biotechnology finance sector. The future ofOpusPoint Partners indeed looks promising with Dr. Rosenwald at its helm.

Kellie McLaughlin, the company’s spokesman, officially confirmed that the company had achieved progress, and he said that it took a real breakthrough to allow termination of an interim trial. Reportedly, more than 1,000 patients, some with severe metastasis expansion and several aggressive chemotherapy courses behind, took part in a research, known as COU-AA-301. The trial was originally invested by leading investment banks, including BioSciences owned by Lindsay Rosenwald, MD.

Another study – COU-AA-302 – aimed at researching the conditions of patients with metastatic prostate cancer, is currently under way. It is being applied to patients who have not received chemotherapeutic treatment courses thus far. Instead, they are getting intensive abiraterone-prednisone treatment as a part of the anti-cancer research.

In his report for BioWorld Today, Kimberly Lee, a Hunter Global Securities analyst, is optimistic about the abiraterone Phase III and MDV-3100, considering more than satisfactory Phase II results and the drugs’ similar effects. However, there is another promising, FDA-approved drug, which is actually a pioneering anti-cancer drug in the U.S. – Dendreon Corp.’s Provenge (sipuleucel-1). Provenge has proven effective against metastatic prostate cancer. For this reason, the discinception of abiraterone is not expected to take any significant effect on Provenge sales. However, though neither abiraterone nor MDV3100 can compete with Provenge, it might be possible to combine these drugs. This is where additional investments will be very handy and Dr. Lindsay Rosenwald and his analysts already think about the possible funding of a new research. In any event, it will take additional research to evaluate the degree of risk posed by the use of Provenge – a potent immune stimulant – in combination with immune suppressants, which are normally used along with abiraterone.

According to David Hung, President and Chief Executive Officer of Medivation, theoretically, abiraterone can be used along with Provenge. In his report, he noted several properties of MDV3100, which ensure improvement in many separate aspects, and an improvement in overall survival statistics among patients, who have received Provenge treatment.

In partnership with Astellas Pharma Inc., Medivation continues the research on MDV3100 and has yet three major trials to complete. Involved in the studies will be patients with early-stage prostate tumors.

Johnson & Johnson acquired Cougar Biotechnology Inc. in July 2009, and thus purchased abiraterone. Cougar, Los Angeles, previously funded by Lindsay Rosenwald’s investment bank, is now J&J’s subsidiary operating in conjunction with Ortho Biotech Oncology Research & Development – a J&J affiliate group.

Abiraterone acetate was licensed by Cougar in 2004 from BTG plc of the UK. This license agreement permits BTG to outline marketing strategies and entitles it to royalties, providing the product is properly formulated and is granted sale permission.

Some analysts, such as Piper Jaffray, who are well aware of BTG marketing dynamics, predict abiraterone sales to reach $1.2 billion by 2018.

At www.muckety.com, Dr. Lindsay Rosenwald’s relationship to the Republican Jewish Coalition is visually illustrated in a diagram-like map.

www.youtube.com/watch?v=s485sqUgSzc

Dr. Lindsay Rosenwald has a profile on Wellness.com that displays his education, current practice, and services offered.  He is a graduate of Temple University Medical School, and he presently works as a general practitioner in New York City.  As a general practitioner, Dr. Lindsay Rosenwald provides an array of services which include bone density testing, immunizations, physical examinations, and stress reduction plans.

The NyICECATS have recognized Dr. Lindsay Rosenwald on multiple occasions as an exceptional member of the organization’s adult team.  The NyICECATS is a Jewish Orthodox youth hockey organization that has branched out to adults.  At both the third and fourth annual Captain’s Dinner, held on March 12^th at Le Marais in New York City, Dr. Lindsay Rosenwald was honored and presented with gifts by Neil Herskowitz, who is the Director of Manhattan Pharmaceutical, Inc.  The gifts of team included a Bauers 190.  As the night went on, Dr. Lindsay Rosenwald made an announcement that he was committed to playing hockey at the Piers for 25 more years.  The dinner concluded with the “Golden Balls” award ceremony.

A search for Dr. Lindsay Rosenwald in the Huffington Post’s FundRace of 2008 displays his donation to the McCain Victory Committee of $61,800.

Dr. Lindsay Rosenwald can also be known to start companies which were the inventories to the new drugs that help the human life a lot by curing the diseases that affect human body by making them weak. Cougar Biotechnology and Polarx Biopharmaceuticals are the two most popularly known companies under the foundation of Rosenwald. These two companies invented two new drugs in addition to the older ones. Though these drugs are being developed by the companies under Rosenwald’s guidance they are being allowed to enter the market after few medical tests. Drugs are the one which are known scientifically as life Savers.

All the inventions and developments of the drugs are done by highly qualified people related to various fields of Biotechnology under scientific research. It can be said that the team is grouped in accordance to the experts who are highly skilled with the practical and theoretical knowledge. The formulation of the drug and its manufacturing are done in a process like technology transfer, pharmacology and toxicology aspects of the drug, clinical development, regulatory, marketing, etc. The sacrifices of these team members are valued with the success selling of their products in the market.

It is Dr. Lindsay Rosenwald was a person by whom many new young Biotechnologists where inspired and laid new ways to further success. Drugs under Rosenwald’s foundation helped to cure more deadly diseases which can be thought as the one having no treatment. Rosenwald was the one with two invaluable features which were both as per financial and physician analysts.

Dr. Lindsay Rosenwald reputed himself as a corporate finance managing director for D.H. Blair & Company, in the year of 1988. This was a privately owned investment based business. There, he was the leader of a team of three physician-financiers that sought through the medical community for any new and profitable break-through that could make use of private investment. They located various schools of medicine, universities, hospitals, drug companies, study groups, and scientific firms. He has worked within the biotechnology and bioresearch disciplines. Dr. Rosenwald serves on the Columbia-Presbyterian Health Sciences Advisory Counsel and in the 2002 article edition of Genetic Engineering News he was ranked number one in the list of 100 Molecular Millionaires with a worth of $617,721,671. Dr. Lindsay Rosenwald operated on the Keryx Biopharmaceutical, Inc board of directors from 2002 to 2006. He quit in order to contribute additional time performing in the biotechnology market. Cougar Biotechnology, purchased by Johnson & Johnson in 2009, is another business that was first founded by Dr. Rosenwald and was originated completely on abiraterone acetate. Abiraterone Acetate, even though it had not yet attained phase III in clinical testing trials, was showing so much potential in the therapy and management for prostate cancer that Johnson & Johnson offered a short-term unification bid and procurement  for the Cougar Biotechnology corporation for $1 billion. Dr. Lindsay Rosenwald, apart from the scores of ventures which have imparted financing and resources to portfolio companies, has also began the Rosenwald Foundation. This is a nonprofit outfit that has been triumphant in offering millions of dollars in aid of many medical and scientific instruction institutions.

Rosenwald graduated from Abington High School in Pennsylvania in 1973. He went on to attend Penn State University and graduated as a part of the Betta Gamma Sigma business school honor society in 1977, having received his degree in finance. He then attended Temple University’s School of Medicine where he receive his doctorate in 1983. He began work in Abington Medical Hospital but started a private practice soon thereafter. Taking his abilities from his private practice to Wall Street, Lindsay Rosenwald began using both finance specialization and his unique insights into the medical industry to work in an advisory capacity. This would become the foundation of the work for which he is best known.

He has helped these companies (once they have been located ans supported) by assisting them in making effective corporate plans, business strategies, and provide basic business and strategic support. These landmark companies have all been a significant part of Lindsay Rosenwald‘s contribution to the industry, and are behind his widely acknowledged reputation as one of the forerunners in the biomedical industry, both as a contributor, entrepreneur, and developer. Over the last two decades, repeated success has solidified this reputation. The companies that he has established, developed, or invested in, have had an immense impact on the industry as a whole. The contributions have not only been financially successfully, but revolutionary in the industry, making significant progress in treatment for prostate cancer, leukemia, dense tumors, and more. Lindsay Rosenwald and his contributions do not seem to be waning. Rather, over the last three years, we have seen a significant increase in the number of investments made. The innumerable accomplishments that Lindsay Rosenwald’s work has led to in the biotechnology and bioresearch fields include a few notable highlights. From a financial perspective, we have seen major success, with notable examples like Sanctura. The impact on the medical field itself, with astonishing progress in areas like leukemia, tumor, and cancer treatment, are just a few of the more significant items of note. The acquisitions from outside companies may be one of the greatest signals of how successful Lindsay Rosenwald has been. Groups like Johnson & Johnson, Albany Molecular, and Myriad Pharmaceuticals, have acquired portfolio and the total cost of acquisitions have exceed $1 billion. All of this success may root back to the double disciplines that Lindsay Rosenwald chose to pursue.

Having experience in both the financial sector and in medicine and biotechnology, Lindsay Rosenwald has been able to offer insights that are matched by few others in the history of modern healthcare. He is not only able to seek out those companies which show great potential, he is also able to accurately foresee the challenges they may face, and prepare them with resources and strategies to cope with those challenges successfully. Lindsay Rosenwald has selflessly established the Rosenwald foundation. This nonprofit organization has contributed millions of dollars to medical education institutions and other scientific communities, laying the groundwork for the revolutionary advances of the future. Lindsay Rosenwald has many accomplishments that he can successfully claim. He is the founder of a company which has led to some of the greatest pharmaceutical and biotechnology advancements over the last two decades. He is a successful entrepreneur and forerunner in the finance industry. His dual disciplines in finance and medicine have allowed him to have an impact that few others have had in the history of biomedicine, and in recent years, Lindsay Rosenwald is widely seen as the greatest contributor to the industry.

www.youtube.com/watch?v=rZI3tAvqa1o